Cure Today1d
The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
Merck Races to Launch Subcutaneous Keytruda Amid Looming Patent Expiry for IV Version
Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.
Cure Today2d
Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...
Subcutaneous options offer convenience for patients — and a valuable window for drugmakers
From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...
Healio1d
FDA grants biologics license application for monthly IV Leqembi
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...
pharmaphorum3d
FDA sets August date for subcutaneous Leqembi decision
To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...
The American Journal of Managed Care8d
Subcutaneous Ocrelizumab Well Tolerated in Patients With MS
Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...
Zacks.com on MSN3d
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...